362 related articles for article (PubMed ID: 16167051)
1. Gastrointestinal stromal tumors and the evolution of targeted therapy.
Sanborn RE; Blanke CD
Clin Adv Hematol Oncol; 2005 Aug; 3(8):647-57. PubMed ID: 16167051
[TBL] [Abstract][Full Text] [Related]
2. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
3. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
[TBL] [Abstract][Full Text] [Related]
4. Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy.
Heinrich MC; Corless CL
J Surg Oncol; 2005 Jun; 90(3):195-207; discussion 207. PubMed ID: 15895440
[TBL] [Abstract][Full Text] [Related]
5. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
Shiba K; Matsumoto T; Hirota S
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).
Negri T; Bozzi F; Conca E; Brich S; Gronchi A; Bertulli R; Fumagalli E; Pierotti MA; Tamborini E; Pilotti S
J Pathol; 2009 Jan; 217(1):103-12. PubMed ID: 18973210
[TBL] [Abstract][Full Text] [Related]
7. Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours.
Renouf DJ; Wilson L; Blanke CD
Clin Cancer Res; 2009 Jun; 15(12):3908-11. PubMed ID: 19509180
[TBL] [Abstract][Full Text] [Related]
8. Management of gastrointestinal stromal tumors in the imatinib era: selected case studies.
Benjamin RS; Blanke CD; Blay JY; Bonvalot S; Eisenberg B
Oncologist; 2006 Jan; 11(1):9-20. PubMed ID: 16401709
[TBL] [Abstract][Full Text] [Related]
9. Pathology of gastrointestinal stromal tumors.
Hirota S; Isozaki K
Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
[TBL] [Abstract][Full Text] [Related]
10. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P
Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858
[TBL] [Abstract][Full Text] [Related]
11. [Imatinib and solid tumours].
Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
[TBL] [Abstract][Full Text] [Related]
12. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal stromal tumours: clinical overview, surgery and recent advances in imatinib mesylate therapy.
Samelis GF; Ekmektzoglou KA; Zografos GC
Eur J Surg Oncol; 2007 Oct; 33(8):942-50. PubMed ID: 17196360
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P
Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470
[TBL] [Abstract][Full Text] [Related]
15. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal stromal tumors.
von Mehren M; Watson JC
Hematol Oncol Clin North Am; 2005 Jun; 19(3):547-64, vii. PubMed ID: 15939196
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors.
Romeo S; Debiec-Rychter M; Van Glabbeke M; Van Paassen H; Comite P; Van Eijk R; Oosting J; Verweij J; Terrier P; Schneider U; Sciot R; Blay JY; Hogendoorn PC;
Clin Cancer Res; 2009 Jun; 15(12):4191-8. PubMed ID: 19509155
[TBL] [Abstract][Full Text] [Related]
18. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
Griffin JM; Amand MS; Demetri GD
Clin J Oncol Nurs; 2005 Apr; 9(2):161-9. PubMed ID: 15853160
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic targets in gastrointestinal stromal tumors].
Wardelmann E; Schildhaus HU; Merkelbach-Bruse S; Büttner R
Verh Dtsch Ges Pathol; 2006; 90():73-9. PubMed ID: 17867582
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives.
Papaetis GS; Syrigos KN
Cancer Metastasis Rev; 2010 Mar; 29(1):151-70. PubMed ID: 20112054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
